Revenues in 2018-2019
Invest in IPO CureVac
CureVac (CVAC) is a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. CureVac vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs.
CureVac technology platform is based on a natural approach to optimize mRNA constructs that encode functional proteins that replace defective or missing proteins using the cell’s intrinsic translation machinery.This platform is built on three core pillars: protein design, mRNA optimization and mRNA delivery. The company was founded in 2000 with headquarters in Germany. It currently has over 450 employees, including over 116 employees with advanced scientific degrees. CureVac has raised €1.03 billion in gross proceeds from a combination of equity and convertible debt financings with an additional €95 million of external committed financing outstanding.
CureVac current product portfolio includes clinical and preclinical candidates across multiple disease indications in oncology, prophylactic vaccines and protein therapy. The lead clinical program is CV8102, which is in a Phase 1 clinical trial for the treatment of four types of solid tumors. The global solid tumor cancer treatment market was valued at $121B in 2018 and is expected to reach $424.6B by 2027, expanding at a CAGR of 15% from 2019 to 2027. This represents a huge opportunity for the company in the coming years. CureVac is also engaged in a clinical program for CV7202, which is in a Phase 1 clinical trial for potential vaccination against rabies.
Additionally, the company is rapidly advancing mRNA vaccine program against coronavirus SARS- CoV-2, for which CureVac initiated a Phase 1 clinical trial in healthy volunteers in June 2020, with results expected in the fourth quarter of 2020. CureVac owns approximately 693 issued patents worldwide, including 49 issued U.S. patents and 50 issued European patents; 119 pending U.S. patent applications, 79 pending European patent applications and 314 pending patent applications in other foreign countries.
Even if CureVac consummates this offering, it will require substantial additional financing, which may not be available on acceptable terms, or at all. Raising additional capital may cause dilution to shareholders, including purchasers of common shares in this offering, restrict operations or require CureVax to relinquish rights to technology or product candidates.
CureVac depends on strategic partnerships with other companies to assist in the research, development and commercialization of its platform and product candidates. If existing or future partners do not perform as expected and if CureVac fail to maintain any of these collaborations, its ability to commercialize product candidates successfully and to generate revenues through technology licensing may be materially adversely affected.
CureVac primarily generates revenue from its licensing and development agreements with collaboration partners for the development of mRNA medicines against a variety of targets in diseases and conditions. It booked $20 million in revenue for the 12 months ended March 31, 2020.
CureVac plans to raise $200 million by offering 13.3 million shares at a price range of $14 to $16. The company plans to raise an additional $118 million in a concurrent private placement to insider Dietmar Hopp. Over the past 6 months biotech IPOs have shown high returns of about 50%. The most recent offerings were iTeos Therapeutics +52%, Nurix Therapeutics -6%, Berkeley Lights +164%.
2-3 weeks before the start of the company publishes information about the opening of trading: financial statements for 3 years, a description of the company's business, plans for the future, as well as the risks that management sees in their own business. We analyze such offers and publish the best ones. Investors apply for deposits. Before the deadline for applications, you can change the request or cancel it.
We submit one large application for the purchase of shares by pre-subscription with reduced price to large investors. The application may be rejected in part or in full. Over the past three years, our applications have been rejected only three times. The next day, or every other day, we'll know at what price and at what percentage the order is executed, and we'll post it on «The my investment page».
The price of shares is rising from the first day due to the demand of investors deprived of the opportunity to buy shares before trading. Most of the stocks we've been recommending buying over the past three years have been starting to trade on the stock exchange at tens of percent higher than the price at which customers bought the shares. There comes a Lock up period when it is forbidden to sell shares purchased by subscription. Typically lasts 3 months.
After the expiration of the Lock Up period, the investment is automatically closed and the investor receives a profit on account of the deduction commissions UT. You can always view the results of your past investments in investment archive.
Although no shares are allowed to be sold during the lock-up period, our traders seek to offer investors fixed profit by way of using various financial instruments, including forwards, options, short positions etc.
From the investor’s point of view this means that he or she may close an investment by paying a certain part of its value (as a rule, approximately 15 percent). This is due to high prices for the instruments which are employed to ensure availability of fixed profit. As such, you shall press any relevant button in the Investor Account as soon as it is active.
The closing procedure is similar to commencement of investment business. You shall file a bid which is executed within a business day by UT. So, your investment is closed at the price currently prevailing on the stock exchange. However, we rarely recommend using this feature, since upon expiry of an applicable lock-up period the average performance is higher.
3 per cent of the share price. This fee is charged as soon as your investment bid is confirmed.
1.75 per cent of the purchase price paid for your shares as soon as trading is closed. This fee is charged upon closure of any relevant investment.
20 per cent of the profit your derive. This fee is charged only if you show positive performance as of the moment any relevant investment is closed.
TO EARLY EXIT
Usually, 15 per cent (depends on the stock exchange environment). It is calculated per each investment individually.
Our risk managers ensure proper support throughout the entire transaction. Moreover, you may call them on +7 495 646-15-57 or 8 800 333-66-81 or visit our office, if a more detailed discussion is needed.
IN THE PROFIT FROM THE FIRST DAY
Such an approach allows it to limit extra risks related to bankruptcy of start-ups and considerably increase profit vs investors purchasing shares on open Market.
LOW ENTRY THRESHOLD
Millions of dollars are required to buy shares on a subscription basis. We have generated a pool of traders and investors which enables any newbie to participate in any transaction as aforesaid by investing just USD50 or more.